The Confirmatory Olmesartan Plaque Regression Study

NCT01132768 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

114

Enrollment

INDUSTRY

Sponsor class

Stopped Low recruitment

Conditions

Essential Hypertension
Carotid Plaque

Interventions

DRUG: Atenolol
DRUG: olmesartan medoxomil

Sponsor

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company